|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-3-3
|
|
pubmed:abstractText |
Retrospective studies have demonstrated the prognostic impact of genomic profiles in neuroblastoma (NB). Segmental chromosome alterations have been found useful for identifying tumors with a high risk of relapse. As the gain of chromosome arm 17q is the most frequent chromosome alteration reported in NB primary tumors, we evaluated the presence of this 17q gain in the peripheral blood of patients with NB.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/BIRC5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Inhibitor of Apoptosis Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-3,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/TP53 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/myelopoietin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1545-5017
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
757-61
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21370407-Case-Control Studies,
pubmed-meshheading:21370407-Chromosome Aberrations,
pubmed-meshheading:21370407-Chromosomes, Human, Pair 17,
pubmed-meshheading:21370407-Comparative Genomic Hybridization,
pubmed-meshheading:21370407-DNA, Neoplasm,
pubmed-meshheading:21370407-Female,
pubmed-meshheading:21370407-Gene Amplification,
pubmed-meshheading:21370407-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:21370407-Humans,
pubmed-meshheading:21370407-In Situ Hybridization, Fluorescence,
pubmed-meshheading:21370407-Infant,
pubmed-meshheading:21370407-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:21370407-Interleukin-3,
pubmed-meshheading:21370407-Male,
pubmed-meshheading:21370407-Neuroblastoma,
pubmed-meshheading:21370407-Polymerase Chain Reaction,
pubmed-meshheading:21370407-Prognosis,
pubmed-meshheading:21370407-Recombinant Fusion Proteins,
pubmed-meshheading:21370407-Recombinant Proteins,
pubmed-meshheading:21370407-Retrospective Studies,
pubmed-meshheading:21370407-Sensitivity and Specificity,
pubmed-meshheading:21370407-Survival Rate,
pubmed-meshheading:21370407-Tumor Markers, Biological,
pubmed-meshheading:21370407-Tumor Suppressor Protein p53
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA.
|
|
pubmed:affiliation |
Centre Léon Bérard, Laboratoire de Recherche Translationnelle, Lyon Cedex, France. combaret@lyon.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
